NALLELY GARCIA-RAMOS: Open Payments
NPI 1295457547 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$579 in 29 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $469 · 2025 $579
Food & beverage: $579
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $227 |
| AstraZeneca Pharmaceuticals LP | 3 | $142 |
| PFIZER INC. | 2 | $49 |
| Boston Scientific Corporation | 1 | $43 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Astellas Pharma US Inc | 2 | $28 |
| Lilly USA, LLC | 1 | $21 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
Products named: Ozempic, AIRSUPRA, Wegovy, PREVNAR 20, APOLLO ESG System, FARXIGA, Veozah, AMYVID.
Industry payments across TX — which companies pay providers there.
